Clinical Guide to Probiotic Products Available in Canada: 2018 Edition

INDICATIONS FOR ADULT HEALTH

Brand Name Probiotic Strain Dosage Form CFU/Dose No of Doses/Day Indications (Level of Evidence)
Activia®* B. (animalis) lactis CNCM Ferm. milk lq. 1B/serving 1-3 servings C - Constipation (I)
I-2494 IBS - Irritable bowel syndrome (I)
Align® B. longum 35624 Capsules 1B/capsule 1 capsule IBS - Irritable bowel syndrome (I) HC
Align® Chewables B. longum 35624 Tablet 1B/Tablet 1 tablet IBS - Irritable bowel syndrome (I) HC
Bio-K+® CL1285* L. acidophilus CL 1285 Ferm, soy lq 50B/tub ½ -1 tub AAD - Antibiotic associated diarrhea - Prevention (I) HC
L. casei LBC80R Strong Capsule 25B/capsule 1-2 capsules CDAD - Clostridium difficile associated diarrhea -
L. rhamnosus CLR2 Ferm. milk lq. 50B/tub ½ -1 tub Prevention (I) HC
“Travel Protection” 30B/capsule 1-2 capsules
Ferm. rice lq. 50B/tub ½ -1 tub
Regular Capsule 12.5B/capsule 1-2 capsules
Extra Strength 50B/capsule 1-2 capsules
BioGaia® L. reuteri DSM 17938 Chew. tabs 100M/tab 1 tab AAD - Antibiotic associated diarrhea - Prevention (II)
ProTectis® Chew C - Constipation (I) HC
tabs HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
ID - Infectious diarrhea (II)
BioGaia® L. reuteri DSM 17938 Drops 100M/5drops 5 drops AAD - Antibiotic associated diarrhea - Prevention (II)
ProTectis® Drops C - Constipation (I) HC
HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
ID - Infectious diarrhea (II)
BioGaia® L. reuteri DSM 17938 Drops 100M/5drops 5 drops AAD - Antibiotic associated diarrhea - Prevention (II)
ProTectis® Drops C - Constipation (I)
with Vitamin D HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
ID - Infectious diarrhea (II)
CalmBiotic™ B. longum R0175 Stick 3B CFU/stick 1 stick M/A - Mood and Affect (symptoms related to
L. helveticus R0052 stress/anxiety; not a substitute for standard treatment)
(II)
CulturedCare™ Streptococcus salivarius Lozenge 0.5B/lozenge 2-10 lozenges OH - Oral health (reductions of tonsillitis, laryngitis, and
ProbioticGum K12 dental caries) (II) HC

2018 Version, valid until Dec. 31, 2018. © BHSoftInc

 Clinical Guide to Probiotic Products Available in Canada: 2018 Edition
INDICATIONS FOR ADULT HEALTH

Brand Name Probiotic Strain Dosage Form CFU/Dose No of Doses/Day Indications (Level of Evidence)
Culturelle® L. rhamnosus GG Capsule 10B/capsule 1 capsule AAD - Antibiotic associated diarrhea - Prevention (I) HC
HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
DanActive®* L. casei sp. Paracasei Ferm. milk lq. 10B/serving 1-2 servings AAD - Antibiotic associated diarrhea - Prevention (I)
CNCM I-1518 CID - Common infectious disease - community
acquired (I)
Digestive Care™ L. plantarum 299v Capsule 10B/capsule 1-2 capsule AAD - Antibiotic associated diarrhea - Prevention (III)
Daily Probiotic CDAD - Clostridium difficile associated diarrhea -
Prevention (III)
IBS - Irritable bowel syndrome (I) HC
Digestive Care™ L. rhamnosus GG Capsule 10B/capsule 1 capsule AAD - Antibiotic associated diarrhea - Prevention (I)
Travel Probiotic HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
FlorastorMax® Saccharomyces boulardii Sachet 10B/sachet 1 sachet AAD - Antibiotic associated diarrhea - Prevention (I) HC
lyo CNCM I-745 CDAD - Clostridium difficile associated diarrhea -
Prevention (I)
HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
IBD-UC - IBD - Ulcerative colitis - Adjunct to standard
therapy (III)
TD - Traveler’s diarrhea prevention (I)
Florastor® Saccharomyces boulardii Sachet 5B/sachet 1-2 sachets AAD - Antibiotic associated diarrhea - Prevention (I) HC
lyo CNCM I-745 Capsule 5B/capsule 1-2 capsules CDAD - Clostridium difficile associated diarrhea -
Prevention (I)
HP - Helicobacter pylori - Adjunct to standard
eradication therapy (I)
IBD-UC - IBD - Ulcerative colitis - Adjunct to standard
therapy (III)
TD - Traveler’s diarrhea prevention (I)

2018 Version, valid until Dec. 31, 2018. © BHSoftInc

 Clinical Guide to Probiotic Products Available in Canada: 2018 Edition
INDICATIONS FOR ADULT HEALTH

Brand Name Probiotic Strain Dosage Form CFU/Dose No of Doses/Day Indications (Level of Evidence)
GoodBelly® L. plantarum 299v Liquid 20B/serving (8 oz) 1 serving AAD - Antibiotic associated diarrhea - Prevention (III)
Probiotic Juice CDAD - Clostridium difficile associated diarrhea -
Drinks Prevention (III)
IBS - Irritable bowel syndrome (I)
HMF by Genestra L. acidophilus CUL60 Intensive 25B/capsule 1-2 capsule CDAD - Clostridium difficile associated diarrhea -
L. acidophilus CUL21 Capsule 2.5B/capsule 1-2 capsule Prevention (II)
B. bifidum CUL20 Super Powder 10B/1 scoop 1-2 scoops IBS - Irritable bowel syndrome (II)
B. lactis CUL34 Forte (1gram) 1-2 capsule
Intensive 50 10B/capsule 1 capsule
50B/capsule
Mutaflor®* Echerichia coli Nissle Capsule 2.5-25B/capsule 1-2 capsules IBD-UC - IBD - Ulcerative colitis - Adjunct to standard
1917 therapy (I)
PerioBalance™ L reuteri ATCC 55730 Lozenge 100M each/lozenge 2 lozenges OH - Oral health (reductions of tonsillitis, laryngitis, and
L reuteri ATCC PTA 5289 dental caries) (II) HC
Probiotic Sticks Bifdobacterium longum Stick 3B CFU/stick 1 stick M/A - Mood and Affect (symptoms related to
R0175 stress/anxiety; not a substitute for standard treatment)
L. helveticus R0052 (II) HC
TuZen® L. plantarum 299v Capsule 10B/capsule 1-2 capsules AAD - Antibiotic associated diarrhea - Prevention (III)
CDAD - Clostridium difficile associated diarrhea -
Prevention (III)
IBS - Irritable bowel syndrome (I) HC
Ultra Probiotic L. acidophilus CUL60, Capsule 25B/ 50B/ 75B per 1-2 capsule CDAD - Clostridium difficile associated diarrhea -
Complex by GNC L. acidophilus CUL21, Packet capsule 1-2 packets Prevention (II)
B. bifidum CUL20, 25B/packet IBS - Irritable bowel syndrome (II)
B. lactis CUL34
UltraFlora® Control B. animalis ssp. Lactis 420 Capsule 10B CFU/capsule 1 capsule WM - Weight Management (aids in reduction of body
(B420) weight, body fat mass and waist circumference) (I) HC
UltraFlora® Cold L plantarum HEAL9 Capsule 0.5B each per 1 capsule CID - Common infectious disease - community
Support L. paracasei 8700:2 capsule acquired (I) HC

2018 Version, valid until Dec. 31, 2018. © BHSoftInc

 Clinical Guide to Probiotic Products Available in Canada: 2018 Edition
INDICATIONS FOR ADULT HEALTH

Brand Name Probiotic Strain
UltraFlora® L. plantarum 299v
Intensive Care
Visbiome™* L. acidophilus SD5212
L. casei SD5218
L. bulgaricus SD5210
L. plantarum SD5209
B longum SD5219
B. infantis SD5220
B. breve SD5206
S. thermophilus SD5207
VSL#3®* L. acidophilus SD5212
L. casei SD5218
L. bulgaricus SD5210
L. plantarum SD5209
B longum SD5219
B. infantis SD5220
B. breve SD5206
S. thermophilus SD5207
Dosage Form CFU/Dose No of Doses/Day Indications (Level of Evidence)
Capsule 10B CFU/cap 2 capsules AAD - Antibiotic associated diarrhea - Prevention (III)
CDAD - Clostridium difficile associated diarrhea -
Prevention (III)
IBS - Irritable bowel syndrome (I) HC
Sachet 450B/sachet 1-4 sachets C - Constipation (II) HC
IBD-P - Inflammatory bowel disease - Pouchitis (I) HC
IBD-UC - IBD - Ulcerative colitis - Adjunct to standard
therapy (I) HC
LH - Liver Health (NASH/NAFLD/MHE; as adjunct to
standard therapy; see studies for specific population) (I)
Sachet 450B/sachet 1-4 sachets C - Constipation (II)
IBD-P - Inflammatory bowel disease - Pouchitis (I) HC
IBD-UC - IBD - Ulcerative colitis - Adjunct to standard
therapy (I) HC
LH - Liver Health (NASH/NAFLD/MHE; as adjunct to
standard therapy; see studies for specific population) (I)

* - Product requires refrigeration

HC - Approved by Health Canada

Level of Evidence
Level (I) Evidence obtained from at least one properly designed randomized trial. (HIGHEST LEVEL)
Level (II) Evidence obtained from well-designed controlled trials without randomization. Evidence obtained from well-designed cohort or case-control analytic studies, preferably from
more than one center or research group. Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be
regarded as this type of evidence
Level (III) Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

2018 Version, valid until Dec. 31, 2018. © BHSoftInc

 Clinical Guide to Probiotic Products Available in Canada: 2018 Edition
INDICATIONS FOR ADULT HEALTH

Disclaimer
The statements made regarding products listed here have not been evaluated by the Food and Drug Administration or Health Canada (unless otherwise indicated).
These products are not intended to diagnose, treat, cure or prevent any disease.
Products, services, information and other content provided on this Site, including information that may be provided on this Site directly or by linking to third-party websites are provided for informational purposes only. Please consult with a
physician or other healthcare professional regarding any medical or health related questions. Manufacturer indications for use can be found on product labels.
This chart is reflective of published evidence available to date. It does not represent an endorsement of any specific product. Work on this guide is done independently and without financial conflict. In order to minimize bias, publishing and
distribution efforts are coordinated via Alliance for Education on Probiotics (AEProbio).
We are grateful for unrestricted publishing grant AEProbio is providing for continuous efforts to translate science into clinically applicable form.

2018 Version, valid until Dec. 31, 2018. © BHSoftInc